Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity

Nutrition and Diabetes

Volumn 1, Issue 1, 2011, Pages

  Omar, B ^a   Banke, E ^a   Ekelund, M ^b   Frederiksen, S ^b   Degerman, E ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

adipose tissue; obesity; phosphodiesterase

Indexed keywords

CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ISOENZYME; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE 7B; PHOSPHODIESTERASE 9A; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOCYTE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; ENZYME ACTIVITY; GASTROINTESTINAL SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OMENTUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBCUTANEOUS FAT;

EID: 84884211337     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2011.9     Document Type: Article

References (31)

1. Center for Disease Control and Prevention USoA. Prevalence of overweight and obesity among adults with diagnosed diabetesF United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep 2004; 53: 1066-1068.
2. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747.
3. Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, Stich V et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 2007; 50: 1038-1047.
4. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267-2277.
5. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481-511.
6. Zewail AM, Nawar M, Vrtovec B, Eastwood C, Kar MN, Delgado RM. 3rd Intravenous milrinone in treatment of advanced congestive heart failure. Tex Heart Inst J 2003; 30: 109-113.
7. Hatzimouratidis K. Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. Clin Interv Aging 2006; 1: 403-414.
8. Enoksson S, Degerman E, Hagstrom-Toft E, Large V, Arner P. Various phosphodiesterase subtypes mediate the in vivo antilipolytic effect of insulin on adipose tissue and skeletal muscle in man. Diabetologia 1998; 41: 560-568.
9. Thompson PE, Manganiello V, Degerman E. Re-discovering PDE3 inhibitorsFnew opportunities for a long neglected target. Curr Top Med Chem 2007; 7: 421-436.
10. Xue B, Greenberg AG, Kraemer FB, Zemel MB. Mechanism of intracellular calcium ([Ca2+]i) inhibition of lipolysis in human adipocytes. FASEB J 2001; 15: 2527-2529.
11. Choi YH, Park S, Hockman S, Zmuda-Trzebiatowska E, Svennelid F, Haluzik M et al. Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J Clin Invest 2006; 116: 3240-3251.
12. Zmuda-Trzebiatowska E, Oknianska A, Manganiello V, Degerman E. Role of PDE3B in insulin-induced glucose uptake, GLUT-4 translocation and lipogenesis in primary rat adipocytes. Cell Signal 2006; 18: 382-390.
13. Oknianska A, Zmuda-Trzebiatowska E, Manganiello V, Degerman E. Long-term regulation of cyclic nucleotide phosphodiesterase type 3B and 4 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2007; 353: 1080-1085.
14. Zhang R, Maratos-Flier E, Flier JS. Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology 2009; 150: 3076-3082.
15. Schmitz-Peiffer C, Reeves ML, Denton RM. Characterization of the cyclic nucleotide phosphodiesterase isoenzymes present in rat epididymal fat cells. Cell Signal 1992; 4: 37-49.
16. Snyder PB, Esselstyn JM, Loughney K, Wolda SL, Florio VA. The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J Lipid Res 2005; 46: 494-503.
17. Moro C, Klimcakova E, Lafontan M, Berlan M, Galitzky J. Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptidemediated lipolysis. Br J Pharmacol 2007; 152: 1102-1110.
18. Waddleton D, Wu W, Feng Y, Thompson C, Wu M, Zhou YP et al. Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets. Biochem Pharmacol 2008; 76: 884-893.
19. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 2006; 51: 374-385.
20. Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N et al. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett 2009; 19: 2537-2541.
21. Engfeldt P, Arner P, Bolinder J, Ostman J. Phosphodiesterase activity in human subcutaneous adipose tissue in insulin-and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1982; 55: 983-988.
22. Honnor RC, Dhillon GS, Londos C. cAMP-dependent protein kinase and lipolysis in rat adipocytes. I. Cell preparation, manipulation, and predictability in behavior. J Biol Chem 1985; 260: 15122-15129.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
24. Manganiello V, Vaughan M. An effect of insulin on cyclic adenosine 30:50-monophosphate phosphodiesterase activity in fat cells. J Biol Chem 1973; 248: 7164-7170.
25. Johnson JA, Fried SK, Pi-Sunyer FX, Albu JB. Impaired insulin action in subcutaneous adipocytes from women with visceral obesity. Am J Physiol Endocrinol Metab 2001; 280: E40-E49.
26. Rondinone CM, Carvalho E, Rahn T, Manganiello VC, Degerman E, Smith UP. Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor. J Biol Chem 2000; 275: 10093-10098.
27. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2009.
28. Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY et al. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. J Pharmacol Exp Ther 2009; 329: 571-579.
29. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001; 108: 671-680.
30. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M,Wu L et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010; 159: 842-855.
31. Moro C, Galitzky J, Sengenes C, Crampes F, Lafontan M, Berlan M. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J Pharmacol Exp Ther 2004; 308: 984-992.